Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor...

Area of Science:

• Immunology
• Cancer Biology
• Pharmacology

Background:

• Natural killer (NK) cells are crucial for innate anti-tumor immunity, acting without prior antigen sensitization.
• The tumor microenvironment (TME) often suppresses NK cell activity, promoting tumor immune escape and progression.
• Tumor-expressed ligands binding to NK cell checkpoint receptors inhibit NK cell-mediated tumor lysis, despite advances in immunotherapy.

Purpose of the Study:

• To review NK cell checkpoint receptors exploited by tumors to evade immune surveillance.
• To explore current and emerging pharmacological strategies to counteract NK cell suppression by the TME.
• To discuss the potential of combining these therapies with novel antibody reagents like BiKEs and TriKEs for enhanced tumor rejection.

Main Methods:

• Literature review of NK cell checkpoints and their ligands in the tumor microenvironment.
• Analysis of current and investigational pharmacological agents targeting NK cell suppression.
• Exploration of combination strategies involving checkpoint inhibitors and bispecific/trispecific engagers.

Main Results:

• Identified key checkpoint receptors (e.g., KIRs, TIGIT) utilized by tumors to inhibit NK cell function.
• Highlighted pharmacological approaches including small molecule inhibitors and antibodies to block these checkpoints.
• Demonstrated the potential synergistic effect of combining checkpoint blockade with BiKEs/TriKEs for potent anti-tumor activity.

Conclusions:

• Targeting NK cell checkpoints is a promising strategy to restore anti-tumor immunity.
• Pharmacological interventions can overcome TME-mediated NK cell suppression.
• Combination therapies, particularly with BiKEs and TriKEs, offer a potent approach to enhance NK cell-mediated tumor rejection.